Volume 1, Number 2 (July/August 2003)

Bench to Bedside

89

  

Pathogenesis-Based Treatment of Chemotherapy-Induced Nausea and Vomiting—Two New Agents
Rudolph M. Navari, MD, PhD

Walther Cancer Research Center and College of Science, University of Notre Dame, Notre Dame, Indiana

With peer viewpoints by Richard J. Gralla, MD, Multinational Association of Supportive Care in Cancer, New York, New York, and Paul J. Hesketh, MD, Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts

abstract full text 156 kb

107

  

Mechanisms and Management of Neuropathic Pain in Cancer
Judith A. Paice, PhD, RN, FAAN

Cancer Pain Program, Department of Medicine, Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

With peer viewpoints by Nessa Coyle, PhD, NP, FAAN, Supportive Care Program, Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center, New York, New York, and Ricardo A. Cruciani, MD, PhD, Belinda Lobban, NP, and David Lussier, MD, Division of Research, Department of Pain Medicine & Palliative Care, Beth Israel Medical Center, New York, New York

abstract full text 192 kb

121

  

Current Status of Selenium and Other Treatments for Secondary Lymphedema
Frank Bruns, MD, Oliver Micke, MD, and Michael Bremer, MD

Department of Radiotherapy, Hannover Medical School, Hannover, Germany, and Department of Radiotherapy, Münster University Hospital, Münster, Germany

With a peer viewpoint by Peter I. Pressman, MD, and Eleni Tousimis, MD, Department of Surgery, Weill Cornell Medical College of Cornell University, New York, New York

abstract full text 77 kb

Original Research

131

  

Assessment of Hematologic Effects and Fatigue in Cancer Patients with Chemotherapy-Induced Anemia Given Darbepoetin Alfa Every Two Weeks
Saroj Vadhan-Raj, MD, Barry Mirtsching, MD, Veena Charu, MD, Dixon Terry, MPH, Gregory Rossi, PhD, Dianne Tomita, MS, and William P. McGuire, MD

Department of Medicine, M. D. Anderson Cancer Center, Houston, Texas; Center for Oncology Research and Treatment, Dallas, Texas; Pacific Cancer Medical Center, Inc., Anaheim, California; Medical Affairs Department, Amgen Inc., Thousand Oaks, California; and Franklin Square Hospital Center, Baltimore, Maryland

abstract full text 119 kb

Commentary

139

  

Palliative Care and the Ethics of Research: Medicare, Hospice, and Phase I Trials
Ira Byock, MD

Promoting Excellence in End-of-Life Care, a National Program of The Robert Wood Johnson Foundation

full text 24 kb

How We Do It

143

  

Suggestions for Patients on How to Talk With Children About a Parent’s Cancer
Anna C. Muriel, MD, MPH, and Paula K. Rauch, MD

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

full text 26 kb

Clinical Trials

146

  

Clinical Trials in Supportive Care
Current clinical trials in the management of treatment-related nausea and vomiting and neuropathic pain.

full text 23 kb

Observations

104

  

A Major Advance in the Treatment of Spinal Cord Compression

full text 9 kb

104

  

Epoetin Alfa and Chemotherapy: A Summary of Two Studies on Preventive and Maintenance Use

full text 15 kb

142

  

Involuntary Weight Loss: The Forgotten Vital Sign

full text 14 kb

Reader Services

88

  

Guide for Authors

150

  

Reader Commentary Form

© 2003 by BioLink Communictions, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.